๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Rituximab Treatment to Control Epstein-Barr Virus (EBV) Infection in X-Linked Lymphoproliferative Disorder (XLP)

โœ Scribed by Mark, B.J.; Knutsen, A.P.

Book ID
119276957
Publisher
Elsevier Science
Year
2006
Tongue
English
Weight
158 KB
Volume
117
Category
Article
ISSN
1097-6825

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Differential cellular susceptibility to
Differential cellular susceptibility to Epstein-Barr virus infection in a patient with X-linked lymphoproliferative disease
โœ Motohiko Okano; Geoffrey M. Thiele; Thomas G. Gross; Jack R. Davis; David T. Pur ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 925 KB

## Abstract Epsteinโ€Barr virus (EBV) is often associated with lethal lymphoproliferative disease in immunologically compromised individuals. Recently, we have studied a 20โ€monthโ€old boy with Xโ€linked lymphoproliferative disease (XLP) who had succumbed to infectious mononucleosis (IM) complicated by

Cell-mediated immunity to Epstein-Barr v
Cell-mediated immunity to Epstein-Barr virus (EBV) and natural killer (NK)-cell activity in the X-linked lymphoproliferative syndrome
โœ Shinji Harada; Thomas Bechtold; Janet K. Seeley; David T. Purtilo ๐Ÿ“‚ Article ๐Ÿ“… 1982 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 522 KB

## Abstract The activity of Tโ€cellโ€mediated immunity to Epsteinโ€Barr virus (EBV) was assessed by an assay of regression of the outgrowth of EBVโ€infected autologous B cells. Regression and natural killer (NK)โ€cell activities were compared for patients and their mothers from five families with Xโ€link